Allogene Therapeutics
Ela G. is an experienced finance professional with a robust career spanning over two decades in various accounting and payroll roles. Currently serving as the Associate Director of Payroll and Equity at Allogene Therapeutics since May 2021, Ela previously held the position of Associate Director of Accounting at Nevro from May 2015 to June 2021. Prior to Nevro, Ela was the Controller at Skeletal Kinetics from August 2004 to May 2015, and also served as Assistant Controller at IntraBiotics Pharmaceuticals, Inc. in 2004 and Conceptus from 2001 to 2004. The career began at Solution Soft as an Accounting Manager from 1998 to 2001. Ela G. earned an education from the University of California, Davis, from 1989 to 1992.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.